=> s (parathyroid hormone)/ti
31 PARATHYROID/TI

313 HORMONE/TI

L1 24 (PARATHYROID HORMONE)/TI ((PARATHYROID(W)HORMONE)/TI)

=> s 11 and fy>1986

725713 FY>1986 L2 19 L1 AND FY>1986

=> d 1-5

- 1. 4,508,828, Apr. 2, 1985, Bioassay of **parathyroid**
 hormone; Arnold W. Lindall, et al., 436/500; 422/61; 436/503,
 504, 804, 808, 817, 824, 825 [IMAGE AVAILABLE]
- 2. 4,409,141, Oct. 11, 1983, Peptides for assaying human **parathyroid** **hormone**; Toshiharu Noda, et al., 530/324; 435/7.9; 530/806; 930/10, DIG.787, DIG.821 [IMAGE AVAILABLE]
- 3. 4,105,602, Aug. 8, 1978, Synthesis of peptides with **parathyroid** **hormone** activity; Robert L. Colescott, et al., 524/577; 260/1; 530/324, 327, 328, 330, 331, 334; 930/10, 21, 280, DIG.821, DIG.822 [IMAGE AVAILABLE]
- 4. 4,086,196, Apr. 25, 1978, **Parathyroid** **hormone**; Geoffrey William Tregear, 530/324; 525/54.11; 530/334; 930/10, DIG.821 [IMAGE AVAILABLE]
- 5. 3,886,132, May 27, 1975, Human **parathyroid** **hormone**; Hollis Bryan Brewer, et al., 530/324, 399; 930/10, DIG.821 [IMAGE AVAILABLE] => d ti ab date in ccls 3-5

US PAT NO: 4,105,602 [IMAGE AVAILABLE] L3: 3 of 5 TITLE: Synthesis of peptides with **parathyroid** activity

ABSTRACT:

Resin peptides useful in the preparation of peptides having biological activity, and particularly such resin peptides containing R--CH.sub.2 --O--Phe--Asn at one end of an amino acid

chain, R being the resin and Phe and Asn being the residues of the amino acids phenylalanine and asparagine; and processes for the preparation of such resin peptides. Resin peptides are disclosed which contain amino acid chains identical with the amino acid chains of natural peptides having biological activity. Other resin peptides are disclosed which contain amino acid chains in which the amino acid residues differ in kind and sequence from amino acid chains of natural biologically active peptides but from which peptides having biological acitivity may be derived.

TITLE: Synthesis of peptides with **parathyroid**
hormone activity

US PAT NO: 4,105,602 DATE ISSUED: Aug. 8,

1978 [IMAGE AVAILABLE]

APPL-NO: 05/548,718 DATE FILED: Feb. 10,

1975 INVENTOR: Robert L. Colescott, Bourbonnais, IL

Geoffrey W. Tregear, Hawthorne, Australia

US-CL-CURRENT: 524/577; 260/1; 530/324, 327, 328, 330, 331, 334;

930/10, 21, 280, DIG.821, DIG.822

US PAT NO: 4,086,196 [IMAGE AVAILABLE] L3: 4 of 5

TITLE: **Parathyroid** **hormone**

ABSTRACT:

A peptide chosen from the group comprising [Ala.sup.1]-HPTH-(1-X) and HPTH-(1-X) wherein X is an integer from 27 to 34.

TITLE: **Parathyroid** **hormone**

US PAT NO: 4,086,196 DATE ISSUED: Apr. 25,

1978 [IMAGE AVAILABLE]

APPL-NO: 05/563,173 DATE FILED: Mar. 28, 1975 INVENTOR: Geoffrey William Tregear, Hawthorn, Australia

US-CL-CURRENT: 530/324; 525/54.11; 530/334; 930/10, DIG.821

US PAT NO: 3,886,132 [IMAGE AVAILABLE] L3: 5 of 5

TITLE: Human **parathyroid** **hormone**

ABSTRACT:

Human parathyroid hormone was isolated in highly purified form from human parathyroid adenomas. The primary sequence of the amino terminal 34 residues was determined and the peptide of the first 34 residues synthesized.

TITLE: Human **parathyroid** **hormone**

US PAT NO: 3,886,132 DATE ISSUED: May 27,

1975 [IMAGE AVAILABLE]

APPL-NO: 05/423,303 DATE FILED: Dec. 10, 1973 REL-US-DATA: Continuation-in-part of Ser. No. 317,702,

Dec. 21, 1972, abandoned.

INVENTOR: Hollis Bryan Brewer, Potomac, MD

Claude D. Arnaud, Rochester, MN

US-CL-CURRENT: 530/324, 399; 930/10, DIG.821

=> s ((parathyroid hormone)/ab not l1)
36 PARATHYROID/AB
869 HORMONE/AB
29 (PARATHYROID HORMONE)/AB
((PARATHYROID(W)HORMONE)/AB)
L4 11 ((PARATHYROID HORMONE)/AB NOT L1)

=> d 1-11

- 1. 5,438,040, Aug. 1, 1995, Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same; Nnochiri N. Ekwuribe, 514/3, 4, 12, 21; 530/303, 402, 409, 410, 411 [IMAGE AVAILABLE]
- 2. 5,359,030, Oct. 25, 1994, Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same; Nnochiri N. Ekwuribe, 530/303; 424/85.1, 85.4, 94.3; 435/188; 530/307, 309, 322, 345, 351, 402, 409, 410, 411 [IMAGE AVAILABLE]
- 3. 5,093,233, Mar. 3, 1992, Antagonists with position 13 modification; Michael Rosenblatt, et al., 435/7.21, 4, 7.2, 7.23; 514/12; 530/324, 325; 930/DIG.820, DIG.822 [IMAGE AVAILABLE]
- 4. 4,833,125, May 23, 1989, Method of increasing bone mass; Robert M. Neer, et al., 514/12; 930/10 [IMAGE AVAILABLE]
- 5. 4,788,178, Nov. 29, 1988, Use of gonadoliberin and gonadoliberin agonists for the treatment of climacteric complaints; Wolfgang Konig, 514/15; 930/20, 21, 130, DIG.690 [IMAGE AVAILABLE]
- 6. 4,698,328, Oct. 6, 1987, Method of increasing bone mass; Robert M. Neer, et al., 514/12; 930/10 [IMAGE AVAILABLE]
- 7. 4,692,433, Sep. 8, 1987, Method and composition for regulating serum calcium levels of mammals; Karl Y. Hostetler, et al., 514/12; 424/450; 514/159, 808 [IMAGE AVAILABLE]
- 8. 4,621,053, Nov. 4, 1986, Process for the production of human peptide hormones; Kaname Sugimoto, 435/70.2, 172.2, 240.26, 284, 948; 530/399; 935/106, 109 [IMAGE AVAILABLE]
- 9. 4,423,037, Dec. 27, 1983, Inhibitors of peptide hormone action; Michael Rosenblatt, et al., 514/12; 530/324, 334; 930/10, 20, 21, DIG.821 [IMAGE AVAILABLE]
- 10. 4,369,138, Jan. 18, 1983, Parathyroid radioimmunoassay; Arnold W. Lindall, 530/326; 436/540, 545; 530/324, 854; 930/10 [IMAGE AVAILABLE]
- 11. 4,341,755, Jul. 27, 1982, Parathyroid radioimmunoassay; Arnold W. Lindall, 424/1.45; 436/500 [IMAGE AVAILABLE]

L4: 8 of 4,621,053 [IMAGE AVAILABLE] US PAT NO: 11 ABSTRACT: Human peptide hormones, such as insulin, growth hormone, prolactin, adrenocorticotropic hormone, placental lactogen, calcitonin, **parathyroid** **hormone** and thyroid stimulating hormone, are produced by implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing the human peptide hormone in a non-human warm-blooded animal. After a period of time, the resultant tumor is extracted and disaggregated and then cultured in vitro under conditions appropriate to accumulate the human peptide hormone. The human.times.human hybridoma lymphoblastoid cell line is preferably formed by fusing parent human cells inherently capable of producing the human peptide hormone with a human lymphoblastoid line, preferably of leukemic origin. This process permits a substantial increase in the amount of human peptide hormone which can be produced. => d his (FILE 'USPAT' ENTERED AT 16:50:38 ON 30 AUG 95) 24 S (PARATHYROID HORMONE)/TI L119 S L1 AND FY>1986 L2 L3 5 S L1 NOT L2 11 S ((PARATHYROID HORMONE)/AB NOT L1) L4 => s 11 and fy=198789190 FY=1987 L51 L1 AND FY=1987 => d 4,771,124, Sep. 13, 1988, **Parathyroid** **hormone** antagonists with simplified synthetic methodology; Michael Rosenblatt, et al., 530/324; 930/10, 20, 21 [IMĀĢE AVAILABLE] => s ; 1 and fy=1988ENTER LOGIC EXPRESSION, QUERY NAME, OR (END): ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):-b L6 952270 -B => s 11 and fy=1988 98178 FY=1988 1 L1 AND FY=1988 L7 => d 5,217,896, Jun. 8, 1993, Monoclonal antibodies recognizing **parathyroid** **hormone**-like protein; Steven P. Kramer, et al., 435/240.27, 70.21, 172.2; 530/388.24, 391.1, 391.3 [IMAGE AVAILABLE]

=> s l1 and fy=1989

104232 FY=1989

=> d 1-7 ti,ab,date,in

US PAT NO: 5,171,670 [IMAGE AVAILABLE] L8: 1 of 7

TITLE: Recombinant DNA method for production of

ABSTRACT:

A recombinant DNA molecule coding for human parathyroid hormone operably linked to an inducible bacterial promoter, a leader growth hormone sequence, and a selective enzymatic cleavage site, expression of the molecule in bacteria, and methods for producing large quantities of human parathyroid hormone and its variants.

TITLE: Recombinant DNA method for production of

US PAT NO: 5,171,670 DATE ISSUED: Dec. 15,

1992 [IMAGE AVAILABLE]

APPL-NO: 07/350,979 DATE FILED: **May 12,

1989** INVENTOR: Henry M. Kronenberg, Belmont, MA

Samuel R. Nussbaum, Weston, MA

Tomoko Doi, Osaka, Japan

US PAT NO: 5,028,439 [IMAGE AVAILABLE] L8: 2 of 7

TITLE: Inhibition of **parathyroid** **hormone**

secretion ABSTRACT:

Parathyroid Hormone, when excessively synthesized, induces pathologic bone resorption and demineralization and results in hypocalcemia which produces toxic effects in soft tissues. Non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid, administered orally or systemically, inhibits parathyroid hormone induced bone resorption in vitro and in vivo in warm blooded animals. TITLE:

Inhibition of **parathyroid** **hormone**

secretion US PAT NO: 5,028,439 DATE ISSUED:

Jul. 2, 1991 [IMAGE AVAILABLE]

APPL-NO: 07/296,390 DATE FILED: **Jan. 9, 1989** REL-US-DATA: Continuation of Ser. No. 851,914, Apr. 14,

1986, abandoned, which is a continuation-in-part of Ser. No. 768,394, Aug. 22, 1985, abandoned.

INVENTOR: Abdul Gaffar, Somerset, NJ

US PAT NO: 5,010,010 [IMAGE AVAILABLE] L8: 3 of 7

TITLE: Production of human **parathyroid** **hormone**

from microorganisms

ABSTRACT:

The invention provides recombinant plasmids containing in DNA sequences coding for human preproparathyroid hormone. The invention further provides microorganisms, for example E. coli, transformed by these plasmids. Finally, the invention also provides a plasmid for insertion into yeast and a transformed

yeast in which the plasmid contains DNA coding for parathyroid hormone. Parathyroid hormone is then secreted by the transformed yeast.

Production of human **parathyroid** **hormone** TITLE:

microorganisms from

DATE ISSUED: Apr. 23, US PAT NO: 5,010,010

[IMAGE AVAILABLE] 1991

**Aug. 14, 07/393,851 DATE FILED: APPL-NO:

Continuation of Ser. No. 921,684, Oct. 22, 1989** REL-US-DATA:

abandoned.

INVENTOR: Kaare M. Gautvik, Oslo, Norway

Peter Alestrom, Sollihogda, Norway

Tordis B. Oven, Oslo, Norway Odd S. Gabrielsen, Oslo, Norway

US PAT NO:

L8: 4 of 7 5,001,223 [IMAGE AVAILABLE]

Parathyroid **hormone** antagonists with TITLE:

metabolic properties enhanced

ABSTRACT:

The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein Phe.sup.7 is substituted by NMePhe, D-Phe, desamino Phe, or Met.sup.8 is substituted by NMeMet.

Parathyroid **hormone** antagonists with TITLE:

metabolic properties enhanced

DATE ISSUED: Mar. 19, 5,001,223 US PAT NO:

[IMAGE AVAILABLE] 1991

DATE FILED: **Mar. 2, APPL-NO: 07/318,475

Continuation of Ser. No. 54,360, May 26, 1989** REL-US-DATA: Michael Rosenblatt, Ardmore, PA 1987, abandoned. INVENTOR:

> Lynn H. Caporale, Lansdale, PA Michael Chorev, Jerusalem, Israel

L8: 5 of 7 4,968,669 [IMAGE AVAILABLE] US PAT NO:

Parathyroid **hormone** antagonists TITLE:

ABSTRACT:

The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein Gly.sup.12 is substituted by D-Trp, L-Trp, L- or D- alpha- or beta-naphthylalanine, or D- or L- alpha-MeTrp.

Parathyroid **hormone** antagonists TITLE:

US PAT NO: DATE ISSUED: Nov. 6, 4,968,669

1990 [IMAGE AVAILABLE]

DATE FILED: **Apr. 21, 07/341,597 APPL-NO: Continuation-in-part of Ser. No. 191,512, 1989** REL-US-DATA:

Michael Rosenblatt, Ardmore, PA May 9, 1988. INVENTOR: Michael Chorev, Jerusalem, Israel

US PAT NO:

4,948,789 [IMAGE AVAILABLE]

L8: 6 of 7

TITLE: synthesis and Suppression of **parathyroid** **hormone**

secretion

ABSTRACT:

Vitamin D.sub.3 derivatives of formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, each represent a hydrogen atom or a hydroxyl group; R.sub.4 is hydrogen or a C.sub.4-6 alkyl group that is optionally substituted by a hydroxyl group; preferably 22-oxa-1,25-(OJ).sub.2 D.sub.3, or OCT, are administered to treat hyperparathyroidism, particularly secondary hyperparathyroidism, without inducing hypercalcemia. The derivatives may be administered orally or parenterally. They are preferably administered intravenously in the course of renal dialysis.

Suppression of **parathyroid** **hormone** TITLE:

synthesis and

secretion 4,948,789

DATE ISSUED: Aug. 14,

US PAT NO: 1990

[IMAGE AVAILABLE]

07/329,606 APPL-NO:

DATE FILED: **Mar. 28,

Eduardo Slatopolsky, St. Louis, MO 1989** INVENTOR:

L8: 7 of 7 RE 33,188 [IMAGE AVAILABLE] US PAT NO:

Peptides for assaying human **parathyroid** TITLE:

hormone ABSTRACT:

A peptide of the formula

R--Lys--Lys--Glu--Asp--Asn--Val--Leu--Val--Glu--Ser--His--Glu--Ly s--Ser--

Leu--Gly--Glu--Ala--Asp--Lys--Ala--Asp--Val--Asp--Val--Leu--Thr--Lys--Ala- -Lys--Ser--Gln--OH

wherein R is H, H--Tyr-- or R.sub.1 -- Pro-- Arg--, R.sub.1 is H, H--Tyr-- or R.sub.2 --Ala--Gly--Ser--Gln--Arg--, and R.sub.2 is H, H--Cys-- or H--Tyr--, or a salt thereof, is useful for assaying human parathyroid hormone (h-PTH).

Peptides for assaying human **parathyroid**

DATE ISSUED: **hormone** US PAT NO: RE 33,188

[IMAGE AVAILABLE] Mar. 27, 1990

DATE FILED: **Apr. 3, 07/332,801 APPL-NO: FRN FILED:

1989** FRN-PR. NO: 55-187686

Dec. 29, 1980 FRN-PR. CO: Japan

FRN FILED: Apr. 16, FRN-PR. NO: 56-057691

1981 FRN-PR. CO: Japan

FRN FILED: Sep. 25, 56-152377 FRN-PR. NO:

1981 FRN-PR. CO: Japan

REISSUE OF:

US PAT NO: 4,409,141 DATE ISSUED: Oct. 11, 1983

APPL-NO: 335,401

DATE FILED: Dec. 29, 1981

INVENTOR:

Toshiharu Noda, Shizuoka, Japan Kaoru Morita, Shizuoka, Japan Sadami Kobari, Mishima, Japan Nobuaki Nakagawa, Shizuoka, Japan Susumu Watanabe, Shizuoka, Japan Shigeo Katsuragi, Shizuoka, Japan Kunio Ohyama, Shizuoka, Japan

Masahiko Taniuchi, Mishima, Japan

=> logoff y

U.S. Patent & Trademark Office LOGOFF AT 17:00:10 ON 30 AUG 95